In non-small cell lung cancer (NSCLC), somatic mutations and increased TP53 expression are prevalent, reported at frequencies of approximately 23% and 65%, respectively (Volckmar et al. 2019; Cancer Genome Atlas Research Network 2014). Here, TP53 is linked to non-small cell lung carcinoma.